What is Bioventus's gross profit margin?

What factors drove the changes in Bioventus's revenue and profit?

Did Bioventus beat or miss consensus estimates last quarter?

What were the key takeaways from Bioventus's earnings call?

What does Bioventus do and what are its main business segments?

What were the key takeaways from Bioventus’s earnings call?

What is the revenue and EPS growth rate for Bioventus year over year?

What guidance did Bioventus's management provide for the next earnings period?

- **Q4 Strong Finish**: 10% organic revenue growth, $37M EBITDA, $38M cash flow. PNS/PRP pilots exceed expectations.
- **2025 Milestones**: 150bp EBITDA margin expansion, $75M cash flow, Restorative Therapies record growth.
- **2026 Growth Plan**: $13M investment in PNS/PRP/Ultrasonics, targeting 200+ basis points contribution. Maintain 20% EBITDA margin, reduce leverage below 2x.
- **Segment Outlook**: Pain (+mid-single-digit), Surgical (+double-digit), Restorative (+low-mid-single-digit).

**【CEO Summary Section】**
- **Q4 2025 Performance**: Delivered 10% organic revenue growth, $8M increase in adjusted EBITDA, and $38M cash from operations. PNS and PRP pilot launches showed strong traction, with PNS technology praised for its power, size, and ease of use.
- **2025 Full Year Highlights**: Above-market organic growth across all businesses, 150bp EBITDA margin expansion to 23%, and $75M cash from operations. Restorative Therapies achieved highest growth in 7 years.
- **2026 Objectives**: 
  - **Revenue Growth**: Target 200+ basis points contribution from PNS and PRP, $13M incremental investment in growth drivers (PNS, PRP, Ultrasonics, International).
  - **Profitability**: Maintain 20% EBITDA margin while outpacing revenue growth, driven by gross margin and cost control.
  - **Cash Flow**: Project $82-87M cash from operations, reducing net leverage below 2x by year-end.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: 
  - Revenue: $158M (+3% YoY, 10% organic). Pain Treatments (+15%), Restorative Therapies (+10% ex-divestiture), International (+10% organic).
  - EBITDA: $37M (+30% YoY), margin 23% (+490bp YoY). Gross margin 76% (+180bp YoY).
  - Cash Flow: $38M (vs. $19M YoY), full-year $75M (vs. $39M YoY).
- **2026 Guidance**: 
  - Net Sales: $600-610M (Q1 growth below implied range due to 1 fewer selling day and inventory normalization).
  - EPS: $0.73-0.77 (15-20% growth). Cash from operations +10-17% YoY.
  - Segment Growth: Pain (+mid-single-digit), Restorative (+low-mid-single-digit), Surgical (+double-digit).

**【Q&A Key Highlights】**
- **Pain Treatments**: Volume-driven growth, DUROLANE leading HA performance. 2026 HA growth expected to moderate to market rates to fund PNS/PRP (+200bp contribution).
- **Ultrasonics**: Focus on spine surgery, with marketing and sales expansion. Neurosurgery opportunities secondary but supported by same sales team.
- **PNS/PRP**: PNS pilot success validates technology; PRP leveraging existing HA team. 2026 investments include new GM and scaled commercial resources.
- **International**: 11% organic growth in 2025, targeting continued double-digit growth with expanded team and market access.

Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript

- **Q3 Execution**: 8% organic growth, 19% EBITDA margin, $30M cash flow, validating 2025 guidance.
- **New Product Momentum**: PNS/PRP set to accelerate 2026+ growth.
- **Balance Sheet Strength**: <3x leverage, $42M cash, $300M+ debt reduction.
- **Risk Management**: Tariffs/FX hedged by operational excellence.
- **2025-2026 Transition**: 2025 execution risk/reward balanced.


**【CEO Summary Section】**
- Q3 2025 revenue of $139 million, up 8% organically, driven by above-market growth across all segments.
- Pain treatments revenue accelerated 6% QoQ, led by DUROLANE's strong volume growth and new account wins.
- Surgical solutions grew 9%, with bone graft substitutes (BGS) and ultrasonics leading the charge.
- Restorative therapies (Exogen) achieved double-digit organic growth despite the advanced rehabilitation divestiture.
- New product launches in PNS (StimTrial/TalisMann) and PRP (Excel) are expected to contribute 200+ basis points to 2026 growth.
- Adjusted EBITDA margin expanded 220 bps to 19%, with cash flow from operations tripling QoQ to $30 million.
- 2025 guidance reaffirmed: 6-8% organic revenue growth, $112-116M adjusted EBITDA, $0.64-0.68 EPS.

**【CFO Financial Commentary】**
- Q3 GAAP net income of $13M, up 200% YoY, driven by gross margin expansion and expense savings from divestiture.
- International segment on track for double-digit organic growth, offsetting $5M tariffs/FX headwinds.
- Cash conversion ratio >100%, with year-to-date cash from ops up 88%.

**【Q&A Highlights】**
- DUROLANE outpaced legacy HA therapies, with GELSYN facing price pressure but still contributing to overall portfolio strength.
- BGS distributor ramp-up driving Q4 surgical acceleration, with ultrasonics' clinical differentiation key to penetrating spine market.
- PNS commercial scale-up expected to accelerate 2026 growth, balancing investments with margin expansion.
- 2026 guidance pending, but 2025 execution validates long-term $1B+ vision.

**Key Takeaways**
- **Revenue Growth**: 8% organic Q3 beat with new products (PNS/PRP) set to drive 2026+ expansion.
- **Profitability**: 19% EBITDA margin, $30M+ cash flow, net leverage <3x, debt < $300M by year-end.
- **Risks**: Tariffs/FX ($5M annualized), but strong execution offsetting headwinds.
- **2025 Guidance Reaffirmation**: On track for 6-8% growth, 100+ bps margin expansion.

**2026 Outlook**: PNS/PRP to add 200+ bps growth, positioning for $1B+ with >20%+ margins.


Bioventus Inc. (BVS) Q3 2025 Earnings Call Transcript

- **Q2 Growth**: $148M revenue, 6% organic growth driven by Surgical (+11%) and Exogen (+double-digit). 
- **PNS Launch**: $100M+ potential from StimTrial/TalisMann in fast-growing PNS market. 
- **Cash Flow**: $26M Q2, FY25 target nearly double FY24. 
- **Margins**: 23% EBITDA margin, 100bps expansion target. 
- **Tariffs Impact**: $3M FY25, offset by strong cost control. 
- **Debt Refinancing**: $2M annual savings, extended maturity. 
- **Exogen Recovery**: Targeting $100M+ revenue with mid-single-digit growth.

**【CEO Summary Section】**
- Q2 revenue of $148 million, in line with expectations, with 6% organic growth driven by Surgical Solutions (11% growth) and Restorative Therapies (double-digit growth in Exogen). 
- Adjusted EBITDA of $34 million, up 3% YoY, with margin expansion to 23%. 
- Launched PNS products (StimTrial and TalisMann) targeting $500M+ U.S. market, expected to contribute $100M+ in revenue. 
- Reaffirmed 2025 guidance: 6-8% organic revenue growth, $112-116M adjusted EBITDA, $0.64-0.68 EPS. 
- FY25 cash flow to nearly double YoY, with net leverage <2.5x by year-end. 

**【CFO Financial Commentary】**
- Surgical Solutions: $52M revenue (+11%), driven by ultrasonics and BGS (12% growth). 
- Pain Treatments: $58M (+1%), with HA growth offset by tough comps; DUROLANE volume up mid-single digits. 
- Restorative Therapies: $38M (-32% due to divestiture), Exogen up 11%. 
- Intl: $10M (+12%), organic +24%. 
- Gross margin 76% (up 50bps), OpEx down $4M YoY. 
- Cash flow $26M Q2, +$11M YoY, with $30M revolver draw for debt reduction. 
- Tariffs impact $3M FY25, FX impact $2M absorbed YTD. 

**【Q&A Highlights】**
- **Pain Treatments**: 4-5% organic growth Q2, 6-8% FY25; DUROLANE volume up mid-single digits, IDN wins to accelerate. 
- **BGS**: Q2 growth 10%, accelerating in H2 with new distributors. 
- **Exogen**: Double-digit Q2 growth, targeting $100M+ revenue. 
- **R&D**: Moderate spend, but material % of revenue for PNS/ultrasonics. 
- **Tariffs**: $3M FY25 impact, mostly in H2; FX stable. 
- **PNS Launch**: Limited Q3 rollout, broader 2026; 200bps+ growth contribution potential. 
- **Debt**: 5% annual amortization, $2M interest savings. 
- **Margins**: 100bps EBITDA margin expansion target. 
- **Cash Flow**: $60M+ FY25, up from $32M FY24.

Bioventus (BVS)-6 Aug 25-2025 Q2 Earnings call transcript

- **Q1 Growth Momentum**: $124M revenue (+5% organic), 33% EPS increase to $0.08, driven by Ultrasonics (+50% capital sales) and Exogen expansion.
- **Strategic Priorities**: (1) 6-8% 2025 revenue growth via pain treatment account wins; (2) 100+bps EBITDA margin expansion; (3) Cash flow nearly doubling to $100M+.
- **PRP Partnership**: APEX Biologix XCELL system adds $0+ 2025 revenue, targeting $100M+ PRP market.
- **Tariff Resilience**: Minimal impact ( <$1M/year), 90%+ products U.S.-sourced or exempt.

**【CEO Summary Section】**
- Q1 2025 revenue of $124 million reflected 5% organic growth, driven by double-digit growth in Surgical Solutions (Ultrasonics) and Restorative Therapies (Exogen). Adjusted EPS of $0.08 increased 33% year-over-year.
- Key priorities: (1) Above-market revenue growth through Surgical Solutions expansion and pain treatment account wins; (2) 100+ basis points EBITDA margin expansion via gross margin optimization; (3) Doubling cash flow through reduced interest expenses and operational efficiency.
- Launched PRP partnership with APEX Biologix, targeting synergies with HA treatments and orthopedic surgeons.
- Tariffs currently minimal impact, with 90%+ products sourced in the U.S. or under exemptions.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $19 million (-16% YoY) due to divestiture and $1.1 million FX loss. Gross margin 75% (-70bps YoY) from channel mix and freight costs.
- Operating expenses down $3 million YoY, driven by divestiture savings. Q1 cash outflow ($19M) due to annual bonuses; expect Q2+ cash flow acceleration.
- Full-year guidance reaffirmed: 6-8% organic revenue growth, $112-116M EBITDA, $0.64-0.68 EPS. Net leverage to drop below 2.5x by year-end.

**【Q&A Key Highlights】**
- **Pain Treatment Market**: DUROLANE growth driven by single-injection shift, 10% CMS ASP increase. Q2 2025 growth acceleration expected post-2024 competitor supply issues.
- **Tariff Strategy**: Monitoring but no material impact; 90%+ products U.S.-sourced. Focus on growth execution over external factors.
- **International Expansion**: New OUS leader prioritizing high-potential countries and product launches, targeting disciplined growth.
- **Leverage & M&A**: Targeting <2.0x leverage; open to M&A only for synergistic opportunities (e.g., PRP partnership).

Bioventus (BVS)-6 May 25-2025 Q1 Earnings call transcript

- **Revenue Powerhouse**: 14% organic growth in Q4, 12% total for 2024, driven by Surgical Solutions (+18%) and Pain Treatments (+17%).
- **Profit Machine**: 23% EBITDA growth to $109M, 160bps margin expansion, debt down $50M to 3.0x leverage.
- **2025 Outlook**: $560-570M revenue (+6-8%), 100bps margin expansion, FCF nearly doubles.
- **Growth Engines**: Ultrasonics (+20%+), Exogen (7%+), and DUROLANE (2x market growth) set to accelerate.

**【CEO 2024 Yearly Performance Summary】**
- **Revenue Growth**: 12% total growth (14% organic), driven by Surgical Solutions (18%), Pain Treatments (17%), and Restorative Therapies (7%).
- **Profitability**: Adjusted EBITDA of $109M (+23%), margin expanded 160bps to 19.5%. Debt reduced by $50M, net leverage to 3.0x.
- **Strategic Wins**: Divested Advanced Rehabilitation ($45.4M revenue), onboarding new leadership for Ultrasonics, and reversing 5-year decline in Exogen.

**【CFO 2024 Q4 Financials】**
- **Top Line**: $154M revenue (+14% YoY), Surgical Solutions up 18% (Ultrasonics +20%+), Pain Treatments +17%.
- **Bottom Line**: Adjusted EBITDA $28M (+28%), Adj. EPS $0.15 (+100%). Operating cash flow $19M, FCF to nearly double in 2025.
- **Segment Breakdown**: 
  - **Surgical**: Ultrasonics +20%+, BGS returning to double-digit growth post-supply chain fixes.
  - **Pain**: DUROLANE outperforms market, HA +17%Q4 but expects Q1 headwind from distributor destocking.
  - **Restorative**: Exogen +7% YoY, targeting low-mid single digits in 2025.

**【2025 Financial Guidance】**
- **Revenue**: $560-570M (+6-8% organic), Surgical Solutions to drive double-digit growth.
- **EBITDA**: $112-116M (+8-12%), targeting 100bps margin expansion.
- **Leverage**: Projected to 2.5x by year-end, enabling selective M&A.

**【Q&A Key Takeaways】**
- **Pain Treatments**: DUROLANE growth to continue via volume, not price, with 2x market growth rate.
- **Bone Graft Substitutes**: Supply resolved, targeting double-digit growth in H2 2025.
- **Exogen**: 7%+ growth achievable with improved sales execution.
- **Capital Allocation**: Debt reduction priority, but open to high ROI inorganic opportunities post-2.5x leverage.

Bioventus (BVS)-11 Mar 25-2024 Q4 Earnings call transcript

Bioventus (BVS)-5 Nov 24-2024 Q3 Earnings call transcript

Bioventus Inc - Ordinary Shares (BVS)-6 Aug 24-2024 Q2 Earnings call transcript

Bioventus Inc - Ordinary Shares (BVS)-7 May 24-2024 Q1 Earnings call transcript

Bioventus Inc - Ordinary Shares (BVS)-12 Mar 24-2023 Q4 Earnings call transcript

Bioventus (BVS)-7 Nov 23-2023 Q3 Earnings call transcript

- **HA Franchise Challenges and Recovery**: Despite Q1 2023 HA revenue decline (-11% YoY) due to private payer ASP erosion, volume growth (+high-single digits) signals recovery. Turnaround expected Q4 2023 as rebate renegotiations and lower pricing stabilize margins.
- **Strategic Divestitures**: Wound business divestiture ($30M proceeds) reduces debt and enables focus on core segments. Exploring additional non-core asset sales.
- **Profitability Improvements**: Adjusted EBITDA jumped to $17M (vs. $7M YoY) due to $12M expense reduction. 2023 EBITDA target of $68M+ achievable through Q1 performance extrapolation and margin expansion.
- **Growth Drivers**: Surgical Solutions (12% QoQ growth), Restorative Therapies (11% growth), and International (14% growth) offset HA headwinds. Advanced Rehabilitation and bone graft substitutes lead segment growth.
- **Operational Focus**: CEO prioritizing process improvements, cost control, and leadership stability to rebuild investor confidence.

**【CEO Summary Section】**
- **Strategic Priorities**: Addressing HA franchise challenges, divesting non-core assets (e.g., wound business), and improving profitability.
- **HA Franchise Challenges**: Increased volume through private payer contracts (primarily one payer) caused margin pressure. Rebate renegotiations and lower pricing will reduce future uncertainty. External review to evaluate further actions, with updates expected in Q2.
- **Divestiture Progress**: Wound business divestiture closed with $30M proceeds, reducing debt and quarterly amortization. Exploring additional non-core asset sales.
- **Operational Efficiency**: Initiatives to address inefficiencies from acquisitions and turnover, with progress in back-office processes and integration of Misonix.
- **Segment Performance**: 
  - **Surgical Solutions**: 12% QoQ growth in bone graft substitutes (e.g., OsteoAmp Flowable) and ultrasonics. Q2 slowdown expected due to distributor churn, but long-term double-digit growth forecasted.
  - **Restorative Therapies**: 11% growth driven by Advanced Rehabilitation recovery. Exogen sales stable post-sales force realignment.
  - **International**: 14% growth (18% constant currency) from HA and bone graft substitute recovery post-EU MDR.

**【CFO Financial Commentary】**
- **Q1 2023 Results**: 
  - Revenue: $119M (+2% YoY), $117M constant currency.
  - Adjusted EBITDA: $17M vs. $7M YoY, driven by expense control.
  - HA Revenue: -11% YoY due to ASP decline and private payer mix. Durolane stable, GELSYN volume growth offset pricing headwinds.
  - Gross Margin: 74% (-190bps YoY) due to private payer mix and unfavorable product mix.
  - Operating Expenses: $12M lower YoY from restructuring and cost discipline.
- **Liquidity**: $47M cash, $446M debt. Wound divestiture proceeds reduced revolver draw to $14M.
- **Guidance Delay**: 2023 EBITDA target of $68M+ maintained, but full guidance delayed due to HA private payer review and CartiHeal exit impacts.

**【Q&A Key Highlights】**
- **HA Market Dynamics**: Volume growth (+high-single digits) offset pricing erosion (-low-double digits). Turnaround expected Q4 2023 as ASP stabilizes and private payer contracts mature.
- **Bone Graft Substitute Churn**: Q2 slowdown due to delayed distributor onboarding, but large account wins expected to offset losses in H2.
- **Portfolio Rationalization**: Focusing on businesses with long-term growth potential and ability to invest. No specific divestiture size guidance.
- **EBITDA Drivers**: Revenue growth (HA recovery, Surgical Solutions, International) and expense discipline. 2023 EBITDA target achievable through Q1 performance extrapolation and margin improvements.
- **Leadership Stability**: CEO confident in team's ability to execute turnaround. Commercial team stability improving as confidence in company rebuilds.

Actual	0.24	0.74	0.16	0.25	0.26	0.04	0.1	0.08	-0.06	-0.26	0.14	0.05	0.07	0.07	0.19	0.06	0.15	0.08	0.21	0.15	0.24
Forecast	0.23	0.2817	0.1366	0.1405	0.1763	0.0477	0.1558	0.1229	0.048	-0.15	-0.0033	-0.02	0.0191	-0.0667	0.0672	0.0162	0.0826	0.0246	0.1571	0.1047	0.2158
Surprise	+4.35%	+162.69%	+17.13%	+77.94%	+47.48%	-16.14%	-35.82%	-34.91%	-225.00%	-73.33%	+4342.42%	+350.00%	+266.49%	+204.95%	+182.74%	+270.37%	+81.60%	+225.20%	+33.67%	+43.27%	+11.21%

BVS

BVS fundamentals

BVS Q4 2025 Earnings

Earnings Call

You can ask Aime

BVS

BVS fundamentals

BVS Q4 2025 Earnings

Earnings Call

BVS Earnings Call Summary for Q4/20258:30 AM on Mar 5, 2026

BVS Earnings Call Summary for Q3/20258:30 AM on Nov 4, 2025

BVS Earnings Call Summary for Q2/20258:30 AM on Aug 6, 2025

BVS Earnings Call Summary for Q1/20258:30 AM on May 6, 2025

BVS Earnings Call Summary for Q4/20248:30 AM on Mar 11, 2025

You can ask Aime